By Fineline Cube 
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), announced that IM-101, a Class 1 innovative drug, has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B (CHB). The PreS1-targeted recombinant fusion protein represents a novel therapeutic vaccine approach designed to break immune tolerance and restore HBV-specific immune responses.
Regulatory Milestone
| Parameter | Detail |
|---|---|
| Parent Company | Sino Biopharmaceutical Limited (HKG: 1177) |
| Operating Subsidiary | Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) |
| Drug Designation | IM-101 (Class 1 innovative drug) |
| Regulatory Authority | National Medical Products Administration (NMPA) |
| Approval Type | Clinical trial authorization |
| Indication | Chronic hepatitis B (CHB) |
Drug Profile & Mechanism of Action
Molecular Characteristics
- Class: Therapeutic vaccine for chronic hepatitis B
- Structure: Innovative PreS1-targeted recombinant fusion protein
- Target: PreS1 domain of hepatitis B surface antigen (HBsAg)
- Development Status: First-in-class therapeutic approach in CTTQ pipeline
Immunological Mechanism
- Immune Tolerance Breakthrough: Designed to overcome T-cell exhaustion and immune tolerance characteristic of chronic HBV infection
- HBV-Specific Immunity: Rebuilds virus-specific immune responses through targeted antigen presentation
- Functional Cure Potential: Aims to achieve sustained HBsAg loss and anti-HBs seroconversion without lifelong antiviral therapy
- Therapeutic Paradigm: Shifts from viral suppression to immune-mediated viral clearance
Market Impact & Strategic Implications
- Unmet Medical Need: Addresses 70 million chronic HBV patients in China representing the world’s largest CHB population
- Current Treatment Limitations: Existing nucleos(t)ide analogues suppress viral replication but rarely achieve functional cure (<10% after long-term therapy)
- Competitive Differentiation: First PreS1-targeted therapeutic vaccine in Chinese clinical development
- Commercial Opportunity: Potential to capture significant share of $2.5 billion Chinese CHB therapeutics market
- Global Expansion: Success in China may support international regulatory filings given high global HBV burden
- Pipeline Validation: Demonstrates CTTQ’s capability in complex biologic development and immunotherapy innovation
Strategic Context
The IM-101 approval represents Sino Biopharmaceutical’s strategic expansion into therapeutic vaccines, complementing its established small molecule and biologic portfolio. Chronic hepatitis B remains a critical public health challenge in China, where current treatments fail to address the underlying immune dysfunction that perpetuates viral persistence.
IM-101’s PreS1-targeting approach leverages the immunodominant region of HBV surface antigen, potentially enabling more effective immune recognition compared to conventional HBsAg-based vaccines. The therapeutic vaccine strategy aligns with global efforts to develop functional cure regimens that can eliminate the need for lifelong antiviral therapy.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and market acceptance.-Fineline Info & Tech